Renal Vein Thrombosis Medication
- Author: Igor A Laskowski, MD; Chief Editor: Vincent Lopez Rowe, MD more...
Medication Summary
Reduction in proteinuria is essential in the treatment of renal vein thrombosis (RVT) in patients who are nephrotic. The current standard is ACE inhibition and/or ARBs. Pulmonary emboli from renal vein thrombosis (RVT) should be diagnosed and treated exactly as they are when resulting from other sources (ie, heparin, warfarin). If renal vein thrombosis (RVT) is associated with pulmonary emboli, anticoagulation must be continued as long as nephrotic syndrome is present.
The indicators for thrombolysis in the setting of renal vein thrombosis (RVT) are unclear. No data are available comparing thrombolytic therapy with anticoagulation.[11] In pulmonary embolic disease from other causes, thrombolytics are indicated in the setting of pulmonary hypertension (as found during examination or discovered by echocardiography).
Warfarin, ARBs, and ACEIs are unsafe in pregnancy. Patients with renal vein thrombosis (RVT) in pregnancy are treated best with heparin alone.
Angiotensin-converting enzyme inhibitors
Class Summary
These agents reduce urine protein excretion by decreasing glomerular hydraulic pressure. Decrease efferent arteriolar constriction, thereby decreasing the pressure, resulting in the filtration of protein. The filtered protein, per se, is injurious to the kidney.
Benazepril (Lotensin)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Captopril (Capoten)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Enalapril (Vasotec)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Fosinopril (Monopril)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Lisinopril (Zestril, Prinivil)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Moexipril (Univasc)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Perindopril (Aceon)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This increases levels of plasma renin and reduces aldosterone secretion. In kidney, the drug decreases glomerular hydraulic pressure, thereby decreasing filtration of protein.
Angiotensin receptor blockers
Class Summary
These agents reduce urine protein excretion by decreasing glomerular hydraulic pressure.
Candesartan (Atacand)
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. Use in patients unable to tolerate ACEIs.
Eprosartan (Teveten)
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. Use in patients unable to tolerate ACEIs.
Irbesartan (Avapro)
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. Use in patients unable to tolerate ACEIs.
Losartan (Cozaar)
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. Use in patients unable to tolerate ACEIs.
Telmisartan (Micardis)
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. Use in patients unable to tolerate ACEIs.
Valsartan (Diovan)
Prodrug that produces direct antagonism of angiotensin II receptors. Displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. May induce more complete inhibition of renin-angiotensin system than ACEIs, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. For use in patients unable to tolerate ACEIs.
Harris SL, Smith MP, Laurie A, Darlow BA. Neonatal renal vein thrombosis and prothrombotic risk. Acta Paediatr. Jul 2010;99(7):1104-7. [Medline].
Reimold EW, Wittel RA. Renal venous thrombosis in children: changes in management. South Med J. Oct 1983;76(10):1277-84. [Medline].
Dutta TK, Venugopal V. Venous thromboembolism: the intricacies. J Postgrad Med. Jan-Mar 2009;55(1):55-64. [Medline].
Dauger S, Michot C, Garnier A, Hurtaud-Roux MF. [Neonatal renal venous thrombosis in 2008]. Arch Pediatr. Feb 2009;16(2):132-41. [Medline].
Decoster T, Schwagten V, Hendriks J, Beaucourt L. Renal colic as the first symptom of acute renal vein thrombosis, resulting in the diagnosis of nephrotic syndrome. Eur J Emerg Med. Apr 20 2009;[Medline].
Basterrechea Iriarte F, Sota Busselo I, Nogués Pérez A. [Evolution of imaging in renal vein thrombosis in the newborn]. An Pediatr (Barc). Nov 2008;69(5):442-5. [Medline].
Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. Mar 2003;41(3):565-70. [Medline].
Jaako Dardashti V, Bekassy ZD, Ljung R, Gelberg J, Wingren P, Simonsen O, et al. Successful thrombolysis of neonatal bilateral renal vein thrombosis originating in the IVC. Pediatr Nephrol. Mar 24 2009;[Medline].
Janvier AL, Hamdan H, Malas M. Bilateral renal vein thrombosis and subsequent acute renal failure due to IVC filter migration and thrombosis. Clin Nephrol. May 2010;73(5):408-12. [Medline].
Maroni BJ. Protein restriction in the pre-end-stage renal disease (ESRD) patient: who, when, how, and the effect on subsequent ESRD outcome. J Am Soc Nephrol. Dec 1998;9(12 Suppl):S100-6. [Medline].
McCarthy E, Mahony NO, Guiney M, Ryan JM. Successful catheter directed thrombolysis of IVC and renal vein occlusive thrombus. Ir Med J. Nov-Dec 2011;104(10):311-2. [Medline].
Babu SC, Manoni T, Shah PM. Malignant renal tumor with extension to the inferior vena cava. The American Journal of Surgery. 1998;176:137 -139.
Borrello JA. Renal MR angiography. Magn Reson Imaging Clin N Am. Feb 1997;5(1):83-93. [Medline].
Irish AB, Green FR, Gray DW, et al. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation. Aug 27 1997;64(4):604-7. [Medline].
Kim HS, Fine DM, Atta MG. Catheter-directed thrombectomy and thrombolysis for acute renal vein thrombosis. J Vasc Interv Radiol. May 2006;17(5):815-22. [Medline].
Markowitz GS, Brignol F, Burns ER, et al. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis. May 1995;25(5):801-6. [Medline].
Meehan SM, Limsrichamrern S, Manaligod JR, et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol. Jun 2003;34(6):533-40. [Medline].
Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol. Jul 2003;23(4):406-11. [Medline].
Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. Apr 23 1998;338(17):1202-11. [Medline].
Zini L, Haulon S, Leroy X, et al. Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro- or suprahepatic caval thrombus. BJU Int. Jun 2006;97(6):1216-20.
Print
